In the summer of 2019, my mother was put on a GLP-1 for type-two diabetes. The drug worked. The paperwork — the insurance denials, the pharmacy that kept running out, the coupon program that quietly expired, the clinical counseling nobody had time to give her — did not. I spent eight weeks of evenings on the phone with a health-care system I had spent a decade covering. I could not get a straight answer about what she was taking or why it was so hard to keep.

That was the week I started writing what would, three years later, become the first issue of Wellness Wire. The working title on my laptop was The Receipts. I still think of it that way.

Here is the version of that story we tell new hires. In 2019 there were roughly four kinds of health writing in the American press. There was the trade magazine, written for clinicians and inaccessible to everyone else. There was the lifestyle vertical, written for advertisers. There was the wire-service brief, written by reporters who had been given twenty minutes to summarize a trial. And there was the long-form magazine feature, which was the form I loved most, and which was built to run six times a year — which meant it never covered the thing that happened last Tuesday.

None of those four could hold the conversation around the drugs that were about to reshape primary care. Not the GLP-1s; not the compounded supply chains; not the at-home peptides; not the telehealth operators underwriting any of it. What those stories needed was something that read like a feature and moved like a wire — and that could tell you, when a new trial dropped at noon, what it actually said by dinner.

Four of us — two reporters, a pharmacist, and me — put out the first issue out of a co-working space in downtown Brooklyn. Eight stories. Forty-two paying subscribers in the first week, most of them people I had cold-emailed a PDF. We missed our second week's deadline by three days. We have not missed one since.

We are, today, a staff of nineteen, half of them clinicians. We publish on the web, in your inbox twice a week, and — for the past two years — in a paper quarterly that we print on a small press in the Hudson Valley and mail to anyone who wants one. We take no pharmaceutical advertising. We take no industry underwriting. The only money we take is from readers, and the only thing we owe, in return, is the best read of the evidence we can file that week.

That promise is in the receipts at the bottom of every piece. Every number has a footnote. Every claim has a source. Every reviewer has a name. If the evidence does not support the headline, the headline does not run. If we get it wrong — and we do, and we will — we fix it, in public, with the old version visible and the correction dated.

We are not neutral on a handful of things. We think the gap between trial evidence and clinical reality is where most of the interesting questions in medicine live, and we write toward that gap. We think the patient is the reader, not the subject. We think a good health story is the one you would want your sister to have read before she started a drug that is going to be in the conversation for a decade.

If that is the read you are looking for, I hope you will subscribe. If it is not, I hope you will tell us why. The masthead email is open and I read every message.